Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.
Pignata S, Bookman M, Sehouli J, Miller A, Penson RT, Taskiran C, Anderson C, Hietanen S, Myers T, Madry R, Willmott L, Lortholary A, Thomes-Pepin J, Aghajanian C, McCourt C, Stuckey A, Wu X, Nishio S, Copeland LJ, He Y, Molinero L, Patel S, Lin YG, Khor VK, Moore KN. Pignata S, et al. Among authors: bookman m. Gynecol Oncol. 2023 Oct;177:20-31. doi: 10.1016/j.ygyno.2023.06.018. Epub 2023 Aug 23. Gynecol Oncol. 2023. PMID: 37625235 Clinical Trial.
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, Myers T, Taskiran C, Robison K, Mäenpää J, Willmott L, Colombo N, Thomes-Pepin J, Liontos M, Gold MA, Garcia Y, Sharma SK, Darus CJ, Aghajanian C, Okamoto A, Wu X, Safin R, Wu F, Molinero L, Maiya V, Khor VK, Lin YG, Pignata S. Moore KN, et al. Among authors: bookman m. J Clin Oncol. 2021 Jun 10;39(17):1842-1855. doi: 10.1200/JCO.21.00306. Epub 2021 Apr 23. J Clin Oncol. 2021. PMID: 33891472 Free PMC article. Clinical Trial.
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.
Landen CN, Molinero L, Hamidi H, Sehouli J, Miller A, Moore KN, Taskiran C, Bookman M, Lindemann K, Anderson C, Berger R, Myers T, Beiner M, Reid T, Van Nieuwenhuysen E, Green A, Okamoto A, Aghajanian C, Thaker PH, Blank SV, Khor VK, Chang CW, Lin YG, Pignata S. Landen CN, et al. Among authors: bookman m. Clin Cancer Res. 2023 May 1;29(9):1698-1707. doi: 10.1158/1078-0432.CCR-22-2032. Clin Cancer Res. 2023. PMID: 36595569 Free PMC article.
Joint ENGOT and GOG Foundation requirements for trials with industry partners.
Vergote I, Coleman RL, Pignata S, Bookman MA, Marth C, Herzog TJ, Gonzalez-Martin A, Copeland LJ; European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation Inc.. Vergote I, et al. Gynecol Oncol. 2019 Aug;154(2):255-258. doi: 10.1016/j.ygyno.2019.04.677. Gynecol Oncol. 2019. PMID: 31331494 No abstract available.
Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
Aghajanian C, Bookman MA, Fleming GF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Jackson CG, Sullivan D, Ratajczak CK, Coleman RL. Aghajanian C, et al. Among authors: bookman ma. Gynecol Oncol. 2021 Aug;162(2):375-381. doi: 10.1016/j.ygyno.2021.05.031. Epub 2021 Jun 8. Gynecol Oncol. 2021. PMID: 34112513 Free article. Clinical Trial.
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
Swisher EM, Aghajanian C, O'Malley DM, Fleming GF, Kaufmann SH, Levine DA, Birrer MJ, Moore KN, Spirtos NM, Shahin MS, Reid TJ, Friedlander M, Steffensen KD, Okamoto A, Sehgal V, Ansell PJ, Dinh MH, Bookman MA, Coleman RL. Swisher EM, et al. Among authors: bookman ma. Gynecol Oncol. 2022 Feb;164(2):245-253. doi: 10.1016/j.ygyno.2021.12.003. Epub 2021 Dec 11. Gynecol Oncol. 2022. PMID: 34906376 Free article. Clinical Trial.
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
Aghajanian C, Swisher EM, Okamoto A, Steffensen KD, Bookman MA, Fleming GF, Friedlander M, Moore KN, Tewari KS, O'Malley DM, Chan JK, Ratajczak C, Hashiba H, Wu M, Dinh MH, Coleman RL. Aghajanian C, et al. Among authors: bookman ma. Gynecol Oncol. 2022 Feb;164(2):278-287. doi: 10.1016/j.ygyno.2021.12.012. Epub 2021 Dec 18. Gynecol Oncol. 2022. PMID: 34930617 Free PMC article. Clinical Trial.
200 results